Author Interviews, Gastrointestinal Disease, Microbiome, Nature / 11.01.2019
Normal Intestinal Microbiome Enhances Intestinal Barrier
MedicalResearch.com Interview with:
[caption id="attachment_46889" align="alignleft" width="132"]
Dr. Jala[/caption]
Dr. Venkatakrishna R Jala, PhD
Assistant Professor
James Graham Brown Cancer Center
Department of Microbiology and Immunology
University of Louisville
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Humans evolved along with their gut microbiota and adapted their physiological activities to help each other. Along with consumption of healthy diets, humans must harbor the appropriate microbiota to convert the foods into available components called metabolites. These microbial metabolites play a critical role in preserving homeostasis, the development of immune systems and preventing adverse events both systemically and locally. Despite the availability of large metagenomics (bacterial sequence) data, and its associations with disease conditions, the functional dynamics of microbiota (good vs bad) in human health or diseases are yet to be defined. The host’s indigenous gut microbiota and its metabolites have emerged as key factors that greatly influence human health and disease, including inflammatory bowel diseases (IBD). IBD patients suffer from leaky gut and increased inflammation.
The current study demonstrates that a microbial metabolite derived from ellagitannin/ellagic acid rich diets (e.g., pomegranate, berries) called ‘urolithin A’ and its synthetic analogue significantly enhance gut barrier function in addition to blocking the unwarranted inflammation in IBD animal models.
Dr. Jala[/caption]
Dr. Venkatakrishna R Jala, PhD
Assistant Professor
James Graham Brown Cancer Center
Department of Microbiology and Immunology
University of Louisville
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Humans evolved along with their gut microbiota and adapted their physiological activities to help each other. Along with consumption of healthy diets, humans must harbor the appropriate microbiota to convert the foods into available components called metabolites. These microbial metabolites play a critical role in preserving homeostasis, the development of immune systems and preventing adverse events both systemically and locally. Despite the availability of large metagenomics (bacterial sequence) data, and its associations with disease conditions, the functional dynamics of microbiota (good vs bad) in human health or diseases are yet to be defined. The host’s indigenous gut microbiota and its metabolites have emerged as key factors that greatly influence human health and disease, including inflammatory bowel diseases (IBD). IBD patients suffer from leaky gut and increased inflammation.
The current study demonstrates that a microbial metabolite derived from ellagitannin/ellagic acid rich diets (e.g., pomegranate, berries) called ‘urolithin A’ and its synthetic analogue significantly enhance gut barrier function in addition to blocking the unwarranted inflammation in IBD animal models.
Dr. Pedersen[/caption]
Professor Oluf Pedersen
Novo Nordisk Foundation Center for Basic Metabolic Research
University of Copenhagen
MedicalResearch.com: What is the background for this study?
Response: We focused our study on healthy people due to the world-wide bottom-up movement among healthy adults to live gluten-free or on a low-gluten diet.
Therefore, we undertook a randomised, controlled, cross-over trial involving 60 middle-aged healthy Danish adults with two eight week interventions comparing a low-gluten diet (2 g gluten per day) and a high-gluten diet (18 g gluten per day), separated by a washout period of at least six weeks with habitual diet (12 g gluten per day).
The two diets were balanced in number of calories and nutrients including the same total amount of dietary fibres. However, the composition of fibres differed markedly between the two diets.
When the low-gluten trend started years back the trend was without any scientific evidence for health benefits. Now we bring pieces of evidence that a low-gluten diet in healthy people may be related to improved intestinal wellbeing due to changes in the intestinal microbiota which to our surprise is NOT induced by gluten itself but by the concomitant change in the type of dietary fibres linked to a low-gluten intake.


![MedicalResearch.com Interview with: Dr. Theodore Satterthwaite MD Assistant professor in the department of Psychiatry, and Cedric Xia, a MD-PhD candidate Perelman School of Medicine at the University of Pennsylvania MedicalResearch.com: What is the background for this study? What are the main findings? Response: Unlike other branches of modern medicine, psychiatry still solely replies on patient reports and physician observations for clinical decision-making. Without biologically-based tests, the diagnostic categories for mental health do not carve nature at its joint. This is evident in the high levels of co-morbidity across disorders and heterogeneity within disorders. Through this research, we studied a large sample of adolescents who completed MRI-based functional imaging, and used recently-developed machine learning techniques to uncover specific abnormalities that are highly predictive of a wide variety of psychiatric symptoms. Essentially, we tried to find brain patterns that were predictive of different types of psychiatric symptoms. We discovered four such brain-guided dimensions of psychopathology: mood, psychosis, fear, and disruptive behavior. While each of these dimensions exhibits a unique pattern of brain connectivity, a common feature of brain anomaly is shared across the dimensions. Notably, in all linked dimensions, the default mode network and fronto-parietal network, two brain regions that usually become increasingly distinct as the brain matures, were abnormally connected. This loss of normal brain network segregation supports the hypothesis that many psychiatric illnesses may be disorders of brain development. MedicalResearch.com: What should readers take away from your report? Response: This study shows that we can start to use the brain to guide our understanding of psychiatric disorders in a way that’s fundamentally different than grouping symptoms into clinical diagnostic categories. By moving away from clinical labels developed decades ago, we can begin to let the biology speak for itself. Our ultimate hope is that understanding the biology of mental illnesses will allow us to develop better treatments for our patients. MedicalResearch.com: What recommendations do you have for future research as a result of this work? Response: This study demonstrates the importance of incorporating vast amounts of biological data to study mental illness across clinical diagnostic boundaries. Moving forward, we hope to integrate genomic data in order to describe pathways from genes to brain to symptoms, which could ultimately be the basis for novel treatments for mental illness. MedicalResearch.com: Is there anything else you would like to add? Response: Future breakthroughs in brain science to understand mental illness requires large amount of data. While the current study takes advantage of one of the largest samples of youth, the size (n=999) remains dwarfed by the complexity of the brain. The neuroscience community is actively working towards collecting higher quality data in even larger samples, so we can validate and build upon the findings. Citation: Cedric Huchuan Xia, Zongming Ma, Rastko Ciric, Shi Gu, Richard F. Betzel, Antonia N. Kaczkurkin, Monica E. Calkins, Philip A. Cook, Angel García de la Garza, Simon N. Vandekar, Zaixu Cui, Tyler M. Moore, David R. Roalf, Kosha Ruparel, Daniel H. Wolf, Christos Davatzikos, Ruben C. Gur, Raquel E. Gur, Russell T. Shinohara, Danielle S. Bassett, Theodore D. Satterthwaite. Linked dimensions of psychopathology and connectivity in functional brain networks. Nature Communications, 2018; 9 (1) DOI: 10.1038/s41467-018-05317-y [wysija_form id="3"] [last-modified] The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.](https://medicalresearch.com/wp-content/uploads/Cross-clinical-diagnostic-categories-200x180.jpg)




















